FBAL is a metabolite without antiproliferative activity.

FBAL er en metabolit uden antiproliferativ aktivitet.

The major metabolite excreted in urine is FBAL, which represents

Udskillelse i fæces er minimal (2, 6%) .

The major metabolite excreted in urine is FBAL, which represents 57% of the administered dose.
http://www.emea.europa.eu/

Hovedmetabolitten som udskilles i urinen er FBAL, der repræsenterer 57% af den indgivne dosis.
http://www.emea.europa.eu/

Finally, -ureido-propionase cleaves FUPA to -fluoro--alanine (FBAL) which is cleared in the urine.

Endeligt spalter -ureido-propionase FUPA til -fluoro --alanin (FBAL) , som udskilles i urinen.

Japanese patients had also about 25% lower Cmax and 34% lower AUC for FBAL than Caucasian patients.

Patienter af japansk oprindelse havde også omkring 25% lavere Cmax og 34% lavere AUC for FBAL end patienter af kaukasisk oprindelse.

The AUC of FBAL increased with age (20% increase in age results in a 15% increase in the AUC of FBAL).
http://www.emea.europa.eu/

FBAL’ s AUC steg med alderen (20% stigning i alder medførte 15% stigning i FBAL’ s AUC).
http://www.emea.europa.eu/

The AUC of FBAL increased with age (20% increase in age results in a 15% increase in the AUC of FBAL) .

FBAL's AUC steg med alderen (20% stigning i alder medførte 15% stigning i FBAL's AUC) .

Finally, β -ureido-propionase cleaves FUPA to α -fluoro-β - alanine (FBAL) which is cleared in the urine.
http://www.emea.europa.eu/

Endeligt spalter β- ureido- propionase FUPA til α- fluoro- β- alanin (FBAL), som udskilles i urinen.
http://www.emea.europa.eu/

There was a small increase in plasma concentrations of capecitabine and one metabolite (5’ -DFCR); there was no effect on the 3 major metabolites (5’ -DFUR, 5-FU and FBAL).
http://www.emea.europa.eu/

Der var en mindre stigning i plasmakoncentrationerne af capecitabin og en af metabolitterne (5’ DFCR), men ingen virkning på de 3 hovedmetabolitter (5’ DFUR, 5- FU og FBAL).
http://www.emea.europa.eu/

There was a small increase in plasma concentrations of capecitabine and one metabolite (5'-DFCR); there was no effect on the 3 major metabolites (5'-DFUR, 5-FU and FBAL) .

Der var en mindre stigning i plasmakoncentrationerne af capecitabin og en af metabolitterne (5'DFCR) , men ingen virkning på de 3 hovedmetabolitter (5'DFUR, 5-FU og FBAL) .

Elimination: the elimination half-life (t1/2 in hours) of capecitabine, 5'-DFCR, 5'-DFUR, 5-FU and FBAL were 0.85, 1.11, 0.66, 0.76 and 3.23 respectively.

Elimination:Eliminationshalveringstiden (t½, timer) for capecitabin, 5'-DFCR, 5'-DFUR, 5-FU og FBAL var 0, 85, 1, 11, 0, 66, 0, 76 og 3, 23.

Elimination: the elimination half-life (t1/ 2 in hours) of capecitabine, 5'-DFCR, 5'-DFUR, 5-FU and FBAL were 0.85, 1.11, 0.66, 0.76 and 3.23 respectively.
http://www.emea.europa.eu/

Eliminationshalveringstiden (t½, timer) for capecitabin, 5 ’ - DFCR, 5 ’ - DFUR, 5- FU og FBAL var 0, 85, 1, 11, 0, 66, 0, 76 og 3, 23.
http://www.emea.europa.eu/

Creatinine clearance was found to influence the systemic exposure to 5’ -DFUR (35% increase in AUC when creatinine clearance decreases by 50%) and to FBAL (114% increase in AUC when creatinine clearance decreases by 50%).
http://www.emea.europa.eu/

Creatininclearance påvirkede den systemiske eksponering af 5 ’ - DFUR (35% stigning i AUC, når creatininclearance aftog med 50%) og FBAL (114% stigning i AUC, når creatininclearance aftog med 50%).
http://www.emea.europa.eu/

Creatinine clearance was found to influence the systemic exposure to 5'-DFUR (35% increase in AUC when creatinine clearance decreases by 50%) and to FBAL (114% increase in AUC when creatinine clearance decreases by 50%) .

Creatininclearance påvirkede den systemiske eksponering af 5'-DFUR (35% stigning i AUC, når creatininclearance aftog med 50%) og FBAL (114% stigning i AUC, når creatininclearance aftog med 50%) .

Gender, presence or absence of liver metastasis at baseline, Karnofsky Performance Status, total bilirubin, serum albumin, ASAT and ALAT had no statistically significant effect on the pharmacokinetics of 5'-DFUR, 5-FU and FBAL.
http://www.emea.europa.eu/

Køn, tilstedeværelse eller fravær af levermetastaser ved baseline, Karnofsky Performance Status, total bilirubin, serum- albumin, ASAT og ALAT havde ingen statistisk signifikant effekt på farmakokinetikken af 5 ’ - DFUR, 5- FU og FBAL.
http://www.emea.europa.eu/

Gender, presence or absence of liver metastasis at baseline, Karnofsky Performance Status, total bilirubin, serum albumin, ASAT and ALAT had no statistically significant effect on the pharmacokinetics of 5'-DFUR, 5-FU and FBAL.

Køn, tilstedeværelse eller fravær af levermetastaser ved baseline, Karnofsky Performance Status, total bilirubin, serum-albumin, ASAT og ALAT havde ingen statistisk signifikant effekt på farmakokinetikken af 5'-DFUR, 5-FU og FBAL.

At the dose of 1250 mg/ m2 on day 14 with administration after food intake, the peak plasma concentrations (Cmax in µg/ ml) for capecitabine, 5'-DFCR, 5'-DFUR, 5-FU and FBAL were 4.67, 3.05, 12.1, 0.95 and 5.46 respectively.
http://www.emea.europa.eu/

Efter en dosis på 1250 mg/ m2 efter indtagelse af føde var peak- plasmakoncentrationerne på dag 14 (Cmax, μg/ ml) for capecitabin, 5 ’ - DFCR, 5 ’ - DFUR, 5- FU og FBAL 4, 67; 3, 05; 12, 1; 0, 95 og 5, 46.
http://www.emea.europa.eu/

At the dose of 1250 mg/m2 on day 14 with administration after food intake, the peak plasma concentrations (Cmax in µg/ml) for capecitabine, 5'-DFCR, 5'-DFUR, 5-FU and FBAL were 4.67, 3.05, 12.1, 0.95 and 5.46 respectively.

Efter en dosis på 1250 mg/m2 efter indtagelse af føde var peak-plasmakoncentrationerne på dag 14 (Cmax, g/ml) for capecitabin, 5'-DFCR, 5'-DFUR, 5-FU og FBAL 4, 67; 3, 05; 12, 1; 0, 95 og 5, 46.